


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-14 (Canceled)

Claim 15 (Currently Amended) A medicament according to formula (I)



(I)

wherein:

n is 1, 2, 3 or 4;

R¹ is selected from

- (a) an optionally substituted straight chain or branched chain C₁₋₆ alkyl group,
- (b) an optionally substituted straight chain or branched chain C₂₋₆ alkenyl group,
- (c) an optionally substituted straight chain or branched chain C₂₋₆ alkynyl group,
- (d) Aryl,
- (e) Aromatic heterocycle,
- (f) Heterocycle, and
- (g) hydrogen;

where the optional substituents in groups (a), (b) and (c) above are selected

from: C₃₋₇ cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR⁹, NR⁹R¹⁰, S(O)_pR⁹, OC(O)R¹⁰, CO₂R⁹, CONR⁹R¹⁰, SO₂NR⁹R¹⁰, halo and NHSO₂R⁹, and where p is 0, 1 or 2;

R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^9 or halo;

R^9 and R^{10} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl;

Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R^{11} , halo, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{11}$, CO_2R^{12} , $NR^{12}SO_2R^{11}$, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$, where R^{11} is straight chain or branched chain C_{1-6} alkyl and R^{12} and R^{13} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl;

Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR^{12} , $NR^{12}R^{13}$, CO_2R^{12} , $NR^{12}CO_2R^{11}$, R^{11} , halo, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $NR^{12}SO_2R^{11}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$; and

Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR^{12} , $NR^{12}R^{13}$, CO_2R^{12} , $NR^{12}CO_2R^{13}$, R^{11} , halo, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $NR^{12}SO_2R^{11}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$,

or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of said compound medicament or said tautomer wherein said medicament is for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

Claim 16-21 (Canceled)